PARSIPPANY, N.J. (AP) – Generic drugmaker Watson Pharmaceuticals Inc. said it received U.S. approval for its generic version of Pulmicort, an inhalable drug used to treat cough and breathing problems caused by asthma and lung disease.
The Food and Drug Administration approved Watson’s budesonide inhalation suspension, which is the chemical equivalent of AstraZeneca’s drug Pulmicort.
AstraZeneca is currently suing Watson over its plan to market the product. Watson says it hopes to launch the drug this year, if it receives a preliminary injunction ruling in its favor.
Pulmicort had sales of $1.1 billion in the last year, according to IMS Health, a prescription monitoring company.
Date: August 1, 2012
Source: Associated Press
Filed Under: Drug Discovery